Many people taking Wegovy, Ozempic or Mounjaro for weight loss or type 2 diabetes have noticed something unexpected: they are drinking less alcohol, smoking fewer cigarettes, or feeling less drawn to compulsive habits. At first, this seemed anecdotal — but the science is catching up, and the findings are striking.

This article explains what we know about GLP-1 medications and addiction, what the research shows, and what it means for you.

How does GLP-1 affect the brain's reward system?

GLP-1 receptors are found not only in the gut and pancreas — they are also present in key areas of the brain that regulate reward and motivation, including the nucleus accumbens and the ventral tegmental area. These are the same regions activated by addictive substances like alcohol, nicotine, opioids, and gambling.

When GLP-1 receptor agonists (such as semaglutide or tirzepatide) activate these brain receptors, they appear to dampen the dopamine-driven reward signal that makes addictive substances feel pleasurable. In animal studies, this has led to dramatic reductions in drug-seeking behaviour. Human data are now beginning to confirm the same effect.

Does GLP-1 medication reduce alcohol consumption?

This is the most studied area. A large real-world study published in Nature Communications (2024) examined over 227,000 people with alcohol use disorder and found that those taking semaglutide had significantly lower rates of alcohol-related hospital events and a greater likelihood of alcohol abstinence compared to those not on the medication.

In a randomised controlled trial published in eBioMedicine (The Lancet, 2024), semaglutide was shown to significantly reduce weekly alcohol consumption and heavy drinking days in people with alcohol use disorder — even at low doses. Participants also reported that alcohol felt less enjoyable.

The effect appears to go beyond simply eating less and therefore drinking less. Semaglutide seems to specifically reduce the brain's reward response to alcohol, making it less appealing as a whole.

Can GLP-1 medication help with smoking?

Here too, the early signals are encouraging. A 2023 study in Addiction found that GLP-1 receptor agonists were associated with reduced nicotine intake in animal models. In humans, patient reports and early observational data suggest that some people on semaglutide find it easier to quit or cut down on smoking.

A large retrospective study using US electronic health records (2024) found that patients prescribed semaglutide had a meaningfully lower risk of being diagnosed with nicotine dependence over the follow-up period compared to matched controls. More randomised trials are underway to confirm these findings.

What about opioids and other substances?

Animal studies have shown that GLP-1 receptor agonists can reduce the self-administration of cocaine, opioids, and methamphetamine. The mechanism involves blunting the dopamine surge that these substances trigger in the brain's reward circuitry.

Human evidence for opioids and other hard substances is still emerging. However, a 2024 analysis of US insurance data found that people on GLP-1 agonists had lower rates of opioid overdose events compared to people on other diabetes or obesity medications. This is a preliminary finding that warrants further study.

Does it affect compulsive behaviours like gambling or binge eating?

Binge eating disorder (BED) has been directly studied, and the results are clear: semaglutide significantly reduces binge eating episodes. A study in Obesity (2023) showed that participants on semaglutide had far fewer episodes of uncontrolled eating than those on placebo, and reported reduced food preoccupation — sometimes called "food noise".

For gambling and other behavioural addictions, the evidence is largely anecdotal and theoretical at this stage, though the shared brain mechanism makes it biologically plausible that GLP-1 medications could help.

Why does this happen biologically?

Addiction — whether to a substance or a behaviour — shares a common neurological pathway: the release of dopamine in the brain's reward centres creates a sense of pleasure that the brain learns to seek again and again. Over time, the brain adjusts by reducing its own dopamine sensitivity, making it harder to feel pleasure without the addictive stimulus.

GLP-1 receptors in the nucleus accumbens and ventral tegmental area appear to regulate this dopamine signalling. When activated by semaglutide or tirzepatide, they seem to reduce the dopamine spike triggered by addictive stimuli — making the reward feel less intense, and therefore less compulsive. This is fundamentally different from how existing addiction treatments (such as naltrexone or varenicline) work, which makes GLP-1 medications a potentially novel class of treatment.

Is GLP-1 medication approved as an addiction treatment?

No — not yet. Wegovy and Ozempic are approved for weight management and type 2 diabetes. Mounjaro and Zepbound are approved for type 2 diabetes and weight management respectively. None of these medications are currently approved by the FDA, EMA, or other regulatory bodies as treatments for alcohol use disorder, smoking cessation, or other addictions.

Multiple clinical trials are underway. Novo Nordisk and academic research groups are running randomised controlled trials on semaglutide for alcohol use disorder and nicotine dependence. Results are expected within the next few years.

What should you do if you notice this effect?

If you are taking a GLP-1 medication and notice reduced cravings for alcohol, cigarettes, or other compulsive behaviours — that is a positive and real effect. You can:

What does the future look like?

The potential of GLP-1 medications in the addiction space is one of the most exciting developments in medicine right now. If the clinical trials confirm what observational data and animal models suggest, we could be looking at a class of medications that simultaneously address obesity, type 2 diabetes, cardiovascular risk, and — perhaps — some of the most difficult-to-treat addictions.

This is not yet clinical reality, but the science is moving fast. Stay tuned, stay curious, and keep talking to your doctor about what is relevant for you.

Medical disclaimer

This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are not approved for the treatment of addiction. If you have concerns about alcohol use, smoking, or other addictive behaviours, please consult a qualified healthcare professional.

Sources